Conformis Establishes Alliance to Focus on ASC Joint Replacement
July 15 2019 - 4:30PM
Conformis, Inc. (NASDAQ: CFMS), a medical technology company that
uses its proprietary iFit Image-to-Implant technology platform to
develop, manufacture and sell patient specific joint replacement
implants designed to fit each patient's unique anatomy, announced
today a new alliance with Regent Surgical Health.
Working together, the organizations will aim to develop
innovative ways to help reduce cost and improve patient outcomes
relating to outpatient total joint replacement in alternative sites
of care.
A privately held surgery center development and management
company in the United States, Regent Surgical Health owns or
operates 26 U.S. surgical facilities, 21 hospital joint ventures, 3
bundled payment entities, and 14 total joint replacement
centers.
“Conformis has transformed joint replacement technology which
has led to better patient outcomes,” said Chris Bishop, CEO of
Regent Surgical Health. “Our collaboration builds on that and
allows us to improve clinical pathways for patients while enhancing
the value proposition for surgeons, employers, and payers.”
“We are pleased to collaborate with Regent Surgical Health to
help bring about improved outcomes and efficiencies in outpatient
total joint surgery,” said Mark Augusti, CEO of Conformis. “It
is clear that payers and providers want to establish a business and
clinical care model that results in better patient outcomes and
enables delivery of total joint arthroplasty resulting in overall
lower cost of care.”
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture and sell joint replacement implants that are
individually sized and shaped, or customized, to fit each patient's
unique anatomy. Conformis offers a broad line of customized
knee and hip implants and customized pre-sterilized, single-use
instruments delivered to the hospital. In clinical
studies, Conformis iTotal CR knee replacement system
demonstrated superior clinical outcomes, including better function
and greater patient satisfaction, compared to traditional,
off-the-shelf implants. Conformis owns or exclusively
in-licenses issued patents and pending patent applications that
cover customized implants and customized patient-specific
instrumentation for all major joints.
For more information, visit www.conformis.com. To
receive future releases in e-mail alerts, sign up
at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the anticipated
timing of our product launches, our collaboration with Regent
Surgical Health and our financial position and results, total
revenue, product revenue, gross margin, operations, as well as
other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "project," "should,"
"target," "will," or "would" and similar expressions, constitute
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995.
We may not actually achieve the forecasts disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual financial results could
differ materially from the projections disclosed in the
forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to our estimates
and expectations regarding our revenue, gross margin, expenses,
revenue growth and other results of operations, and the other risks
and uncertainties described in the "Risk Factors" sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
CONTACT: Investor contact ir@conformis.com (781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024